Cited by 466CAR-T cell therapy researchImmunotherapy and Immune ResponsesCancer Immunotherapy and Biomarkers

The DOI matches its Crossref record; 137 of the 137 references it cites were found in a registry or an index.

Exploiting the curative potential of adoptive T‐cell therapy for cancer

Open access

Hinrichs, Christian S., Rosenberg, Steven A.·2014·Immunological Reviews

DOI 10.1111/imr.12132PMC PMC3920180

Open this paper in CoChat — free account

Abstract

Summary: Adoptive T‐cell therapy (ACT) is a potent and flexible cancer treatment modality that can induce complete, durable regression of certain human malignancies. Long‐term follow‐up of patients receiving tumor‐infiltrating lymphocytes (TIL s) for metastatic melanoma reveals a substantial subset that experienced complete, lasting tumor regression – and may be cured. Increasing evidence points to mutated gene products as the primary immunological targets of TIL s from melanomas. Recent technological advances permit rapid identification of the neoepitopes resulting from these somatic gene mutations and of T cells with reactivity against these targets. Isolation and adoptive transfer of these T cells may improve TIL therapy for melanoma and permit its broader application to non‐melanoma tumors. Extension of ACT to other malignancies may also be possible through antigen receptor gene engineering. Tumor regression has been observed following transfer of T cells engineered to express chimeric antigen receptors against CD 19 in B‐cell malignancies or a T‐cell receptor against NY‐ESO‐1 in synovial cell sarcoma and melanoma. Herein, we review recent clinical trials of TIL s and antigen receptor gene therapy for advanced cancers. We discuss lessons from this experience and consider how they might be applied to realize the full curative potential of ACT.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1111/imr.12132

Cites

137 of 137 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Mutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674
Cancer Genome Landscapes
Vogelstein, B., Papadopoulos, N., Velculescu, V. E., Zhou, S., Diaz, L. A., & Kinzler, K. W. (2013) · Science · doi:10.1126/science.1235122 · Cited by 7,863
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720
Chimeric antigen receptor–modified T cells in chronic lymphoid leukemia
Porter, D. L., Levine, B. L., Kalos, M., Bagg, A., & June, C. H. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103849 · Cited by 3,565
Coordinated regulation of myeloid cells by tumours
Gabrilovich, D. I., Ostrand-Rosenberg, S., & Bronte, V. (2012) · Nature Reviews Immunology · doi:10.1038/nri3175 · Cited by 3,544
Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia
Grupp, S. A., Kalos, M., Barrett, D., Aplenc, R., Porter, D. L., Rheingold, S. R., Teachey, D. T., Chew, A., Hauck, B., Wright, J. F., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215134 · Cited by 3,509
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
Flaherty, K. T., Puzanov, I., Kim, K. B., Ribas, A., McArthur, G. A., Sosman, J. A., O'Dwyer, P. J., Lee, R. J., Grippo, J. F., Nolop, K., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1002011 · Cited by 3,103
Cancer regression in patients after transfer of genetically engineered lymphocytes
Morgan, R. A., Dudley, M. E., Wunderlich, J. R., Hughes, M. S., Yang, J. C., Sherry, R. M., Royal, R. E., Topalian, S. L., Kammula, U. S., Restifo, N. P., et al. (2006) · Science · doi:10.1126/science.1129003 · Cited by 2,603
Self-citation
Case Report of a Serious Adverse Event Following the Administration of T Cells Transduced With a Chimeric Antigen Receptor Recognizing ERBB2
Morgan, R. A., Yang, J. C.-H., Kitano, M., Dudley, M. E., Laurençot, C. M., & Rosenberg, S. A. (2010) · Molecular Therapy · doi:10.1038/mt.2010.24 · Cited by 2,564
Self-citation

Show all 137 references

Sorted by citations

Neoantigens in cancer immunotherapy
Schumacher, T. N., & Schreiber, R. D. (2015) · Science · doi:10.1126/science.aaa4971 · Cited by 4,783
Molecular and genetic properties of tumors associated with local immune cytolytic activity
Rooney, M. S., Shukla, S. A., Wu, C. J., Getz, G., & Hacohen, N. (2015) · Cell · doi:10.1016/j.cell.2014.12.033 · Cited by 3,825
Chimeric antigen receptor T-cell therapy—assessment and management of toxicities
Neelapu, S. S., Tummala, S., Kebriaei, P., Wierda, W., Gutierrez, C., Locke, F. L., Komanduri, K. V., Lin, Y., Jain, N., Daver, N., et al. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.148 · Cited by 2,438
CD4+ T cell help in cancer immunology and immunotherapy
Borst, J., Ahrends, T., Bąbała, N., Melief, C. J. M., & Kastenmüller, W. (2018) · Nature Reviews Immunology · doi:10.1038/s41577-018-0044-0 · Cited by 1,585
Cancer immunotherapy: the beginning of the end of cancer?
Farkona, S., Diamandis, E. P., & Blasutig, I. M. (2016) · BMC Medicine · doi:10.1186/s12916-016-0623-5 · Cited by 1,231
Cytokines in clinical cancer immunotherapy
Berraondo, P., Sanmamed, M. F., Ochoa, M. C., Etxeberría, I., Aznar, M. A., Perez‐Gracia, J. L., Rodriguez-Ruiz, M. E., Ponz‐Sarvisé, M., Álvarez, E. C., & Melero, I. (2018) · British Journal of Cancer · doi:10.1038/s41416-018-0328-y · Cited by 1,218
Therapeutic cancer vaccines
Melief, C. J. M., van Hall, T., Arens, R., OSSENDORP, F. A., & van der Burg, S. H. (2015) · Journal of Clinical Investigation · doi:10.1172/jci80009 · Cited by 1,192
Co-expression of CD39 and CD103 identifies tumor-reactive CD8 T cells in human solid tumors
Duhen, T., Duhen, R., Montler, R., Moses, J., Moudgil, T., de Miranda, N. F., Goodall, C. P., Blair, T. C., Fox, B. A., McDermott, J. E., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-05072-0 · Cited by 938
Nanoparticle design strategies for enhanced anticancer therapy by exploiting the tumour microenvironment
Dai, Y., Xu, C., Sun, X., & Chen, X. S. (2017) · Chemical Society Reviews · doi:10.1039/c6cs00592f · Cited by 939
Toxicity and management in CAR T-cell therapy
Bonifant, C. L., Jackson, H. J., Brentjens, R. J., & Curran, K. J. (2016) · Molecular Therapy — Oncolytics · doi:10.1038/mto.2016.11 · Cited by 911
TRUCKs: the fourth generation of CARs
Chmielewski, M. M., & Abken, H. (2015) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2015.1046430 · Cited by 783
Navigating metabolic pathways to enhance antitumour immunity and immunotherapy
Li, X., Wenes, M., Romero, P. J., Huang, S. C., Fendt, S., & Ho, P. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0203-7 · Cited by 750
Complete Regression of Metastatic Cervical Cancer After Treatment With Human Papillomavirus–Targeted Tumor-Infiltrating T Cells
Stevanović, S., Draper, L. M., Langhan, M. M., Campbell, T. E., Kwong, M. L. M., Wunderlich, J. R., Dudley, M. E., Yang, J. C., Sherry, R. M., Kammula, U. S., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.58.9093 · Cited by 693
Self-citation
Improving cancer immunotherapy through nanotechnology
Goldberg, M. S. (2019) · Nature reviews. Cancer · doi:10.1038/s41568-019-0186-9 · Cited by 628
Cancer Neoantigens
Schumacher, T. N., Scheper, W., & Kvistborg, P. (2018) · Annual Review of Immunology · doi:10.1146/annurev-immunol-042617-053402 · Cited by 587
Relationships Between Immune Landscapes, Genetic Subtypes and Responses to Immunotherapy in Colorectal Cancer
Picard, E., Verschoor, C. P., Grace, W. K., & Pawelec, G. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00369 · Cited by 533
Augmentation of Antitumor Immunity by Human and Mouse CAR T Cells Secreting IL-18
Hu, B., Ren, J., Luo, Y., Keith, B., Young, R. M., Scholler, J., Zhao, Y., & June, C. H. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.09.002 · Cited by 516
Recent Advances in Targeting CD8 T-Cell Immunity for More Effective Cancer Immunotherapy
Durgeau, A., Virk, Y., Corgnac, S., & Mami‐Chouaib, F. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00014 · Cited by 507
Photothermal Therapy Promotes Tumor Infiltration and Antitumor Activity of CAR T Cells
Chen, Q., Hu, Q., Dukhovlinova, E., Chen, G., Ahn, S., Wang, C., Ogunnaike, E. A., Ligler, F. S., Dotti, G., & Gu, Z. (2019) · Advanced Materials · doi:10.1002/adma.201900192 · Cited by 470
Treatment of CD33-directed Chimeric Antigen Receptor-modified T Cells in One Patient With Relapsed and Refractory Acute Myeloid Leukemia
Wang, Q., Wang, Y., Lv, H., Han, Q., Fan, H., Guo, B., Wang, L.-L., & Han, W. (2014) · Molecular Therapy · doi:10.1038/mt.2014.164 · Cited by 424
Tumor microenvironment: barrier or opportunity towards effective cancer therapy
Tiwari, A., Trivedi, R., & Lin, S. (2022) · Journal of Biomedical Science · doi:10.1186/s12929-022-00866-3 · Cited by 399
Engineered Cell‐Membrane‐Coated Nanoparticles Directly Present Tumor Antigens to Promote Anticancer Immunity
Jiang, Y., Krishnan, N., Zhou, J., Chekuri, S., Wei, X., Kroll, A. V., Yu, C. L., Duan, Y., Gao, W., Fang, R. H., et al. (2020) · Advanced Materials · doi:10.1002/adma.202001808 · Cited by 376
Mechanisms regulating T-cell infiltration and activity in solid tumors
Lanitis, E., Dangaj, D., Irving, M., & Coukos, G. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx238 · Cited by 369
Combinational strategy for high-performance cancer chemotherapy
Qin, S., Cheng, Y., Lei, Q., Zhang, A., & Zhang, X. (2018) · Biomaterials · doi:10.1016/j.biomaterials.2018.04.027 · Cited by 304
Tissue-resident memory T cells at the center of immunity to solid tumors
Amsen, D., van Gisbergen, K. P. J. M., Hombrink, P., & van Lier, R. A. W. (2018) · Nature Immunology · doi:10.1038/s41590-018-0114-2 · Cited by 291
Generation of mature T cells from human hematopoietic stem and progenitor cells in artificial thymic organoids
Seet, C. S., He, C., Bethune, M. T., Li, S., Chick, B. Y., Gschweng, E. H., Zhu, Y., Kim, K., Kohn, D. B., Baltimore, D., et al. (2017) · Nature Methods · doi:10.1038/nmeth.4237 · Cited by 282
Making Better Chimeric Antigen Receptors for Adoptive T-cell Therapy
Maus, M. V., & June, C. H. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1433 · Cited by 276
Driving gene-engineered T cell immunotherapy of cancer
Johnson, L. A., & June, C. H. (2016) · Cell Research · doi:10.1038/cr.2016.154 · Cited by 271
Tumour-infiltrating lymphocytes in melanoma prognosis and cancer immunotherapy
Lee, N., Zakka, L. R., Mihm, M. C., & Schatton, T. (2016) · Pathology · doi:10.1016/j.pathol.2015.12.006 · Cited by 250
Immunotherapy of Prostate Cancer: Facts and Hopes
Bilušić, M., Madan, R. A., & Gulley, J. L. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0019 · Cited by 253
Role of tumor-infiltrating lymphocytes in patients with solid tumors: Can a drop dig a stone?
Badalamenti, G., Fanale, D., Incorvaia, L., Barraco, N., Listì, A., Maragliano, R., Vincenzi, B., Calò, V., Iovanna, J., Bazan, V., et al. (2018) · Cellular Immunology · doi:10.1016/j.cellimm.2018.01.013 · Cited by 248
Managing the immune microenvironment of osteosarcoma: the outlook for osteosarcoma treatment
Tian, H., Cao, J., Li, B., Nice, E. C., Mao, H., Zhang, Y., & Huang, C. (2023) · Bone Research · doi:10.1038/s41413-023-00246-z · Cited by 249
The contribution of immune infiltrates and the local microenvironment in the pathogenesis of osteosarcoma
Heymann, M.-F., Lézot, F., & Heymann, D. (2019) · Cellular Immunology · doi:10.1016/j.cellimm.2017.10.011 · Cited by 233
Cancer stem cells: landscape, challenges and emerging therapeutic innovations
Lee, H., Kim, B., Park, J., Park, S., Yoo, G., Yum, S., Kang, W., Lee, J., Youn, H., & Youn, B. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02360-2 · Cited by 247
Harnessing the potential of CAR-T cell therapy: progress, challenges, and future directions in hematological and solid tumor treatments
Dagar, G., Gupta, A., Masoodi, T., Nisar, S., Merhi, M., Hashem, S., Chauhan, R., Dagar, M., Mirza, S., Bagga, P., et al. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-023-04292-3 · Cited by 229
Pediatric pan-central nervous system tumor analysis of immune-cell infiltration identifies correlates of antitumor immunity
Grabovska, Y., Mackay, A. G., O’Hare, P., Crosier, S., Finetti, M. A., Schwalbe, E. C., Pickles, J. C., Fairchild, A. R., Avery, A., Cockle, J. V., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-18070-y · Cited by 211
CRISPR-Cas9: a new and promising player in gene therapy
Xiao-Jie, L., Hui-Ying, X., Zun-Ping, K., Jin-Lian, C., & Li-Juan, J. (2015) · Journal of Medical Genetics · doi:10.1136/jmedgenet-2014-102968 · Cited by 200
Validation of biomarkers to predict response to immunotherapy in cancer: Volume I — pre-analytical and analytical validation
Masucci, G. V., Cesano, A., Hawtin, R. E., Janetzki, S., Zhang, J., Kirsch, I. R., Dobbin, K. K., Alvarez, J. D., Robbins, P. B., Selvan, S. R., et al. (2016) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-016-0178-1 · Cited by 200
Cancer immunotherapy: Challenges and limitations
Taefehshokr, S., Parhizkar, A., Hayati, S., Mousapour, M., Mahmoudpour, A., Eid, L. E., Rahmanpour, D., Fattahi, S., Shabani, H., & Taefehshokr, N. (2021) · Pathology - Research and Practice · doi:10.1016/j.prp.2021.153723 · Cited by 204
Biomedical polymers: synthesis, properties, and applications
Chen, W., Chen, Q., Chen, Q., Cui, C., Duan, S., Kang, Y., Liu, Y., Liu, Y., Muhammad, W., Shao, S., et al. (2022) · Science China Chemistry · doi:10.1007/s11426-022-1243-5 · Cited by 197
Targeting of HPV-16+ Epithelial Cancer Cells by TCR Gene Engineered T Cells Directed against E6
Draper, L. M., Kwong, M. L. M., Gros, A., Stevanović, S., Tran, E., Kerkar, S. P., Raffeld, M. A., Rosenberg, S. A., & Hinrichs, C. S. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-3341 · Cited by 184
Self-citation
Reversal of Tumor Immune Inhibition Using a Chimeric Cytokine Receptor
Leen, A. M., Sukumaran, S., Watanabe, N., Mohammed, S., Keirnan, J. M., Yanagisawa, R., Anurathapan, U., Rendon, D. A., Heslop, H. E., Rooney, C. M., et al. (2014) · Molecular Therapy · doi:10.1038/mt.2014.47 · Cited by 183
CAR T Cell Therapy: A Game Changer in Cancer Treatment
Almåsbak, H., Aarvak, T., & Vemuri, M. C. (2016) · Journal of Immunology Research · doi:10.1155/2016/5474602 · Cited by 186
Metal-free bioorthogonal click chemistry in cancer theranostics
Wu, D., Yang, K., Zhang, Z., Feng, Y., Rao, L., Chen, X. S., & Yu, G. (2022) · Chemical Society Reviews · doi:10.1039/d1cs00451d · Cited by 179
Recent advances in developing active targeting and multi-functional drug delivery systems via bioorthogonal chemistry
Yi, W., Xiao, P., Liu, X., Zhao, Z., Sun, X., Wang, J., Zhou, L., Wang, G., Cao, H., Wang, D., et al. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01250-1 · Cited by 178
Engineered T cells targeting E7 mediate regression of human papillomavirus cancers in a murine model
Jin, B. E., Campbell, T. E., Draper, L. M., Stevanović, S., Weißbrich, B., Yu, Z., Restifo, N. P., Rosenberg, S. A., Trimble, C. L., & Hinrichs, C. S. (2018) · JCI Insight · doi:10.1172/jci.insight.99488 · Cited by 174
Self-citation
Direct Cell Radiolabeling for in Vivo Cell Tracking with PET and SPECT Imaging
Gawne, P. J., Man, F., Blower, P. J., & de Rosales, R. T. M. (2022) · Chemical Reviews · doi:10.1021/acs.chemrev.1c00767 · Cited by 168
Harnessing the tumor microenvironment: targeted cancer therapies through modulation of epithelial-mesenchymal transition
Glaviano, A., Lau, H., Carter, L. M., Lee, E. H. C., Lam, H. Y., Okina, E., Tan, D. J. J., Tan, W., Ang, H. L., Carbone, D., et al. (2025) · Journal of Hematology & Oncology · doi:10.1186/s13045-024-01634-6 · Cited by 169
Multi-phenotype CRISPR-Cas9 Screen Identifies p38 Kinase as a Target for Adoptive Immunotherapies
Gurusamy, D., Henning, A. N., Yamamoto, T. N., Yu, Z., Zacharakis, N., Krishna, S., Kishton, R. J., Vodnala, S. K., Eidizadeh, A., Jia, L., et al. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.05.004 · Cited by 159
Immunological Synapse Predicts Effectiveness of Chimeric Antigen Receptor Cells
Xiong, W., Chen, Y., Kang, X., Chen, Z., Zheng, P., Hsu, Y.-H., Jang, J. H., Qin, L., Liu, H., Dotti, G., et al. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.01.020 · Cited by 157
Tumor-infiltrating T lymphocytes improve clinical outcome of therapy-resistant neuroblastoma
Mina, M., Boldrini, R., Citti, A., Romania, P., D’Alicandro, V., Ioris, M. A. D., Castellano, A., Furlanello, C., Locatelli, F., & Fruci, D. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1019981 · Cited by 154
Chemoattractant Receptors BLT1 and CXCR3 Regulate Antitumor Immunity by Facilitating CD8+ T Cell Migration into Tumors
Chheda, Z. S., Sharma, R. K., Jala, V. R., Luster, A. D., & Haribabu, B. (2016) · The Journal of Immunology · doi:10.4049/jimmunol.1502376 · Cited by 159
In vivo chimeric antigen receptor (CAR)-T cell therapy
Bot, A., Scharenberg, A. M., Friedman, K. M., Guey, L. T., Hofmeister, R., Andorko, J. I., Klichinsky, M., Neumann, F., Shah, J. V., Swayer, A. J., et al. (2025) · Nature Reviews Drug Discovery · doi:10.1038/s41573-025-01291-5 · Cited by 172
Use of HLA peptidomics and whole exome sequencing to identify human immunogenic neo-antigens
Kalaora, S., Barnea, E., Merhavi-Shoham, E., Qutob, N., Teer, J. K., Shimony, N., Schachter, J., Rosenberg, S. A., Besser, M. J., Admon, A., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.6960 · Cited by 148
Self-citation
Intratumor Adoptive Transfer of IL-12 mRNA Transiently Engineered Antitumor CD8+ T Cells
Etxeberría, I., Bolaños, E., Quetglas, J. I., Gros, A., Villanueva, A., Palomero, J., Sánchez-Paulete, A. R., Piulats, J. M., Matías‐Guiu, X., Olivera, I., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.10.006 · Cited by 146
Current Advances in T-Cell-Based Cancer Immunotherapy
Wang, M., Yin, B., Wang, H. Y., & Wang, R. (2014) · Immunotherapy · doi:10.2217/imt.14.86 · Cited by 145
Tumour microenvironment responsive nanoconstructs for cancer theranostic
Gulzar, A., Xu, J., Wang, C., He, F., Yang, D., Gai, S., Yang, P., Lin, J., Jin, D., & Xing, B. (2019) · Nano Today · doi:10.1016/j.nantod.2019.03.007 · Cited by 141
Intratumoral expression levels of PD-L1, GZMA, and HLA-A along with oligoclonal T cell expansion associate with response to nivolumab in metastatic melanoma
Inoue, H., Park, J., Kiyotani, K., Zewde, M. G., Miyashita, A., Jinnin, M., Kiniwa, Y., Okuyama, R., Tanaka, R., Fujisawa, Y., et al. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1204507 · Cited by 137
In Response to Precision Medicine: Current Subcellular Targeting Strategies for Cancer Therapy
Li, Z., Zou, J., & Chen, X. S. (2022) · Advanced Materials · doi:10.1002/adma.202209529 · Cited by 133
HIV-specific CD8+ T cells and HIV eradication
Jones, R. B., & Walker, B. D. (2016) · Journal of Clinical Investigation · doi:10.1172/jci80566 · Cited by 134
Adoptive CD8+ T cell therapy against cancer:Challenges and opportunities
Jiang, X., Jiang, X., Liu, M., Xing, H., Wang, Z., Huang, L., Mellor, A. L., Wang, W., & Wu, S. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.07.017 · Cited by 133
The paradoxical role of cytokines and chemokines at the tumor microenvironment: a comprehensive review
Abdul‐Rahman, T., Ghosh, S., Badar, S. M., Nazir, A., Bamigbade, G. B., Aji, N., Roy, P., kachani, H., Garg, N. K., Lawal, L., et al. (2024) · European journal of medical research · doi:10.1186/s40001-024-01711-z · Cited by 131
The chimeric TAC receptor co-opts the T cell receptor yielding robust anti-tumor activity without toxicity
Helsen, C. W., Hammill, J. A., Lau, V. W. C., Mwawasi, K. A., Afsahi, A., Bezverbnaya, K., Newhook, L., Hayes, D. L., Aarts, C. W., Bojović, B., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-05395-y · Cited by 129
Beyond Tumor Mutation Burden: Tumor Neoantigen Burden as a Biomarker for Immunotherapy and Other Types of Therapy
Wang, P., Chen, Y., & Wang, C. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.672677 · Cited by 130
Dual-specific Chimeric Antigen Receptor T Cells and an Indirect Vaccine Eradicate a Variety of Large Solid Tumors in an Immunocompetent, Self-antigen Setting
Slaney, C. Y., von Scheidt, B., Davenport, A. J., Beavis, P. A., Westwood, J. A., Mardiana, S., Tscharke, D. C., Ellis, S. L., Prince, H. M., Trapani, J. A., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1860 · Cited by 123
Self-citation
Novel CD4-Based Bispecific Chimeric Antigen Receptor Designed for Enhanced Anti-HIV Potency and Absence of HIV Entry Receptor Activity
Liu, L., Patel, B., Ghanem, M. H., Bundoc, V., Zheng, Z., Morgan, R. A., Rosenberg, S. A., Dey, B., & Berger, E. A. (2015) · Journal of Virology · doi:10.1128/jvi.00474-15 · Cited by 121
Self-citation
CXCR6 is required for antitumor efficacy of intratumoral CD8 + T cell
Wang, B., Wang, Y., Sun, X., Deng, G., Huang, W., Wu, X., Gu, Y., Tian, Z., Fan, Z., Xu, Q., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003100 · Cited by 120
CAR T‐cell therapy for pancreatic cancer
DeSelm, C. J., Tano, Z. E., Varghese, A. M., & Adusumilli, P. S. (2017) · Journal of Surgical Oncology · doi:10.1002/jso.24627 · Cited by 116
CAR-T cells and BiTEs in solid tumors: challenges and perspectives
Edeline, J., Houot, R., Marabelle, A., & Alcantara, M. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01067-5 · Cited by 115
You Have Got a Fast CAR: Chimeric Antigen Receptor NK Cells in Cancer Therapy
Pfefferle, A., & Huntington, N. D. (2020) · Cancers · doi:10.3390/cancers12030706 · Cited by 117
Cost of decentralized CAR T‐cell production in an academic nonprofit setting
Ran, T., Eichmüller, S. B., Schmidt, P., & Schlander, M. (2020) · International Journal of Cancer · doi:10.1002/ijc.33156 · Cited by 118
The Expression and Prognostic Impact of Immune Cytolytic Activity-Related Markers in Human Malignancies: A Comprehensive Meta-analysis
Roufas, C., Chasiotis, D., Makris, A., Efstathiades, C., Dimopoulos, C., & Zaravinos, A. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00027 · Cited by 114
Dendritic cells based immunotherapy.
Shang, N., Figini, M., Shangguan, J., Wang, B., Sun, C., Pan, L., Ma, Q., & Zhang, Z. (2017) · PubMed Central · Cited by 109
Rare cancers: a sea of opportunity
Boyd, N., Dancey, J. E., Gilks, C. B., & Huntsman, D. D. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00386-1 · Cited by 107
Personalized Tumor RNA Loaded Lipid-Nanoparticles Prime the Systemic and Intratumoral Milieu for Response to Cancer Immunotherapy
Sayour, E. J., Grippin, A., Leon, G. D., Stover, B. D., Rahman, M., Karachi, A., Wummer, B. M., Moore, G. L., Castillo‐Caro, P., Fredenburg, K. M., et al. (2018) · Nano Letters · doi:10.1021/acs.nanolett.8b02179 · Cited by 107
CARs: Synthetic Immunoreceptors for Cancer Therapy and Beyond
Chang, Z., & Chen, Y. Y. (2017) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2017.03.002 · Cited by 105
The role of cancer stem cells in the modulation of anti-tumor immune responses
Maccalli, C., Rasul, K. I., Elawad, M., & Ferrone, S. (2018) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2018.09.006 · Cited by 105
A comprehensive review on traditional uses, chemical compositions, pharmacology properties and toxicology of Tetrastigma hemsleyanum
Ji, T., Ji, W. W., Wang, J., Chen, H. J., Peng, X. X., Cheng, K., Qiu, D., & Yang, W. J. (2020) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2020.113247 · Cited by 104
Avidity and Bystander Suppressive Capacity of Human Regulatory T Cells Expressing De Novo Autoreactive T-Cell Receptors in Type 1 Diabetes
Yeh, W.-I., Seay, H. R., Newby, B. N., Posgai, A. L., Moniz, F. B., Michels, A. W., Mathews, C. E., Bluestone, J. A., & Brusko, T. M. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01313 · Cited by 106
The Pharmacology of T Cell Therapies
Milone, M. C., & Bhoj, V. G. (2018) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2018.01.010 · Cited by 103
Cancer Testis Antigens and Immunotherapy: Where Do We Stand in the Targeting of PRAME?
Al‐Khadairi, G., & Decock, J. V. (2019) · Cancers · doi:10.3390/cancers11070984 · Cited by 104
Starved and Asphyxiated: How Can CD8+ T Cells within a Tumor Microenvironment Prevent Tumor Progression
Zhang, Y., & Ertl, H. C. J. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00032 · Cited by 102
Toll-like receptor-5 agonist, entolimod, suppresses metastasis and induces immunity by stimulating an NK-dendritic-CD8 + T-cell axis
Brackett, C. M., Kojouharov, B., Veith, J. M., Greene, K. F., Burdelya, L. G., Gollnick, S. O., Abrams, S. I., & Gudkov, A. V. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1521359113 · Cited by 102
Chimeric Antigen Receptor T Cells Guided by the Single-Chain Fv of a Broadly Neutralizing Antibody Specifically and Effectively Eradicate Virus Reactivated from Latency in CD4 + T Lymphocytes Isolated from HIV-1-Infected Individuals Receiving Suppressive Combined Antiretroviral Therapy
Liu, B., Zou, F., Lu, L., Chen, C., He, D., Zhang, X., Tang, X., Liu, C., Li, L., & Zhang, H. (2016) · Journal of Virology · doi:10.1128/jvi.00852-16 · Cited by 101
Ten‐year update of the international registry on cytokine‐induced killer cells in cancer immunotherapy
Zhang, Y., & Schmidt‐Wolf, I. G. H. (2020) · Journal of Cellular Physiology · doi:10.1002/jcp.29827 · Cited by 99
Targeting Macrophages with CAR T Cells Delays Solid Tumor Progression and Enhances Antitumor Immunity
Sánchez-Paulete, A. R., Mateus-Tique, J., Mollaoglu, G., Nielsen, S. R., Marks, A., Lakshmi, A., Khan, J. A., Wilk, C. M., Pia, L., Baccarini, A., et al. (2022) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-21-1075 · Cited by 98
STING activator c-di-GMP enhances the anti-tumor effects of peptide vaccines in melanoma-bearing mice
Wang, Z., & Celis, E. (2015) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-015-1713-5 · Cited by 98
Manufacture of tumor- and virus-specific T lymphocytes for adoptive cell therapies
Wang, X., & Rivière, I. (2015) · Cancer Gene Therapy · doi:10.1038/cgt.2014.81 · Cited by 98
CRISPR-Cas9 therapeutics in cancer: promising strategies and present challenges
Yi, L., & Li, J. (2016) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2016.09.002 · Cited by 96
Immunotherapy of cancers comes of age
Yousefi, H., Yuan, J. D., Keshavarz‐Fathi, M., Murphy, J. F., & Rezaei, N. (2017) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2017.1366315 · Cited by 97
Mutational and Antigenic Landscape in Tumor Progression and Cancer Immunotherapy
Vitale, I., Sistigu, A., Manic, G., Rudqvist, N.-P., Trajanoski, Z., & Galluzzi, L. (2019) · Trends in Cell Biology · doi:10.1016/j.tcb.2019.01.003 · Cited by 95
Adoptive T-cell therapy for cancer: the era of engineered T cells
Bonini, C., & Mondino, A. (2015) · European Journal of Immunology · doi:10.1002/eji.201545552 · Cited by 93
Promising approaches in cancer immunotherapy
Taefehshokr, N., Baradaran, B., Baghbanzadeh, A., & Taefehshokr, S. (2019) · Immunobiology · doi:10.1016/j.imbio.2019.11.010 · Cited by 94
Translational research in oncology—10 years of progress and future prospects
Doroshow, J. H., & Kummar, S. (2014) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2014.158 · Cited by 91
Immunomodulating and Immunoresistance Properties of Cancer-Initiating Cells: Implications for the Clinical Success of Immunotherapy
Maccalli, C., Parmiani, G., & Ferrone, S. (2017) · Immunological Investigations · doi:10.1080/08820139.2017.1280051 · Cited by 90
The role of stem cells in small-cell lung cancer: Evidence from chemoresistance to immunotherapy
Guo, W., Qiao, T., & Li, T. X. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.11.006 · Cited by 86
Injectable Biomimetic Hydrogels as Tools for Efficient T Cell Expansion and Delivery
Weiden, J., Voerman, D., Dölen, Y., Das, R. K., van Duffelen, A., Hammink, R., Eggermont, L. J., Rowan, A. E., Tel, J., & Figdor, C. G. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02798 · Cited by 84
Using chemo-drugs or irradiation to break immune tolerance and facilitate immunotherapy in solid cancer
Zheng, Y., Dou, Y., Duan, L., Cong, C., Gao, A., Lai, Q., & Sun, Y. (2015) · Cellular Immunology · doi:10.1016/j.cellimm.2015.02.003 · Cited by 83
CD123-Engager T Cells as a Novel Immunotherapeutic for Acute Myeloid Leukemia
Bonifant, C. L., Szöőr, Á., Torres, D., Joseph, N. P., Velasquez, M. P., Iwahori, K., Gaikwad, A. S., Nguyen, P., Arber, C., Song, X., et al. (2016) · Molecular Therapy · doi:10.1038/mt.2016.116 · Cited by 84
Thyroid dysfunctions secondary to cancer immunotherapy
Chalan, P., Dalmazi, G. D., Pani, F., Remigis, A. D., Corsello, A., & Caturegli, P. (2017) · Journal of Endocrinological Investigation · doi:10.1007/s40618-017-0778-8 · Cited by 83

Authors: Hinrichs, C. S., & Rosenberg, S. A.
Affiliations: National Cancer Institute (US)
Corresponding author: Hinrichs, Christian S.
ORCID: Hinrichs, Christian S.
Rosenberg, Steven A.
Venue: Immunological Reviews
Publisher: Wiley
Published: 2013-12-13
Volume: 257
Issue: 1
Pages: 56-71
ISSN: 0105-2896 (ISSN-L)
1600-065X
DOI: 10.1111/imr.12132
PMC: PMC3920180
OpenAlex: W2150145041
Cited by: 466
References: 137
Citations by year: 2026: 6 · 2025: 20 · 2024: 16 · 2023: 25 · 2022: 36 · 2021: 32 · 2020: 38 · 2019: 39 · 2018: 55 · 2017: 59 · 2016: 56 · 2015: 56 · 2014: 26 · 2013: 1
FWCI: 4.90
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Licence: onlinelibrary.wiley.com/termsAndConditions#vor (vor)
Locations: Immunological Reviews (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
Funders: National Institutes of Health
National Cancer Institute (ZIABC011478)
Topics: Health Sciences › Medicine › Oncology › CAR-T cell therapy research
Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Keywords: adoptive T cell therapy, tumor-infiltrating lymphocytes, metastatic melanoma, tumor regression, neoantigens, somatic mutations, chimeric antigen receptor, NY-ESO-1, CD19, B-cell malignancies, synovial sarcoma, cancer immunotherapy
MeSH terms: Animals, Antigens, Neoplasm, Humans, Neoplasms, Receptors, Antigen, T-Cell, Protein Engineering, Immunotherapy, Adoptive, Lymphocytes, Tumor-Infiltrating

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Exploiting the curative potential of adoptive T‐cell therapy for cancer

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks